The influence of MOGAD on diagnosis of multiple sclerosis using MRI.
Journal
Nature reviews. Neurology
ISSN: 1759-4766
Titre abrégé: Nat Rev Neurol
Pays: England
ID NLM: 101500072
Informations de publication
Date de publication:
03 Sep 2024
03 Sep 2024
Historique:
accepted:
26
07
2024
medline:
4
9
2024
pubmed:
4
9
2024
entrez:
3
9
2024
Statut:
aheadofprint
Résumé
Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is an immune-mediated demyelinating disease that is challenging to differentiate from multiple sclerosis (MS), as the clinical phenotypes overlap, and people with MOGAD can fulfil the current MRI-based diagnostic criteria for MS. In addition, the MOG antibody assays that are an essential component of MOGAD diagnosis are not standardized. Accurate diagnosis of MOGAD is crucial because the treatments and long-term prognosis differ from those for MS. This Expert Recommendation summarizes the outcomes from a Magnetic Resonance Imaging in MS workshop held in Oxford, UK in May 2022, in which MS and MOGAD experts reflected on the pathology and clinical features of these disorders, the contributions of MRI to their diagnosis and the clinical use of the MOG antibody assay. We also critically reviewed the literature to assess the validity of distinctive imaging features in the current MS and MOGAD criteria. We conclude that dedicated orbital and spinal cord imaging (with axial slices) can inform MOGAD diagnosis and also illuminate differential diagnoses. We provide practical guidance to neurologists and neuroradiologists on how to navigate the current MOGAD and MS criteria. We suggest a strategy that includes useful imaging discriminators on standard clinical MRI and discuss imaging features detected by non-conventional MRI sequences that demonstrate promise in differentiating these two disorders.
Identifiants
pubmed: 39227463
doi: 10.1038/s41582-024-01005-2
pii: 10.1038/s41582-024-01005-2
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. Springer Nature Limited.
Références
Thompson, A. J. et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 17, 162–173 (2018).
pubmed: 29275977
doi: 10.1016/S1474-4422(17)30470-2
Geraldes, R. et al. The current role of MRI in differentiating multiple sclerosis from its imaging mimics. Nat. Rev. Neurol. 14, 199–213 (2018).
pubmed: 29521337
doi: 10.1038/nrneurol.2018.14
Marignier, R. et al. Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol. 20, 762–772 (2021).
pubmed: 34418402
doi: 10.1016/S1474-4422(21)00218-0
Walton, C. et al. Rising prevalence of multiple sclerosis worldwide: insights from the atlas of MS, third edition. Mult. Scler. J. 26, 1816–1821 (2020).
doi: 10.1177/1352458520970841
Filippi, M. et al. Multiple sclerosis. Nat. Rev. Dis. Prim. 4, 43 (2018).
pubmed: 30410033
doi: 10.1038/s41572-018-0041-4
Thompson, A. J., Baranzini, S. E., Geurts, J., Hemmer, B. & Ciccarelli, O. Multiple sclerosis. Lancet 391, 1622–1636 (2018).
pubmed: 29576504
doi: 10.1016/S0140-6736(18)30481-1
Hohlfeld, R., Dornmair, K., Meinl, E. & Wekerle, H. The search for the target antigens of multiple sclerosis, part 1: autoreactive CD4+ T lymphocytes as pathogenic effectors and therapeutic targets. Lancet Neurol. 15, 198–209 (2016).
pubmed: 26724103
doi: 10.1016/S1474-4422(15)00334-8
Reindl, M. & Waters, P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat. Rev. Neurol. 15, 89–102 (2019).
pubmed: 30559466
doi: 10.1038/s41582-018-0112-x
O’Connell, K. et al. Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire, UK. J. Neurol. Neurosurg. Psychiatry 91, 1126–1128 (2020).
pubmed: 32576617
doi: 10.1136/jnnp-2020-323158
Papp, V. et al. Worldwide incidence and prevalence of neuromyelitis optica: a systematic review. Neurology 96, 59–77 (2021).
pubmed: 33310876
pmcid: 7905781
doi: 10.1212/WNL.0000000000011153
Hor, J. Y. et al. Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide. Front. Neurol. 11, 543047 (2020).
doi: 10.3389/fneur.2020.00501
Cobo-Calvo, A. et al. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study. Neurology 90, e1858–e1869 (2018).
pubmed: 29695592
doi: 10.1212/WNL.0000000000005560
Jurynczyk, M. et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain 140, 3128–3138 (2017).
pubmed: 29136091
doi: 10.1093/brain/awx276
Molazadeh, N. et al. Progression independent of relapses in aquaporin4-IgG-seropositive neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, and multiple sclerosis. Mult. Scler. Relat. Disord. 80, 105093 (2023).
pubmed: 37949025
doi: 10.1016/j.msard.2023.105093
Chen, B. et al. Do early relapses predict the risk of long-term relapsing disease in an adult and paediatric cohort with MOGAD? Ann. Neurol. 94, 508–517 (2023).
pubmed: 37394961
doi: 10.1002/ana.26731
Cobo-Calvo, A. et al. Clinical features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody-associated disease. Ann. Neurol. 89, 30–41 (2021).
pubmed: 32959427
doi: 10.1002/ana.25909
Satukijchai, C. et al. Factors associated with relapse and treatment of myelin oligodendrocyte glycoprotein antibody-associated disease in the United Kingdom. JAMA Netw. Open 5, e2142780 (2022).
pubmed: 35006246
pmcid: 8749481
doi: 10.1001/jamanetworkopen.2021.42780
Shahriari, M., Sotirchos, E. S., Newsome, S. D. & Yousem, D. M. MOGAD: how it differs from and resembles other neuroinflammatory disorders. Am. J. Roentgenol. 216, 1031–1039 (2021).
doi: 10.2214/AJR.20.24061
Fadda, G., Armangue, T., Hacohen, Y., Chitnis, T. & Banwell, B. Paediatric multiple sclerosis and antibody-associated demyelination: clinical, imaging, and biological considerations for diagnosis and care. Lancet Neurol. 20, 136–149 (2021).
pubmed: 33484648
doi: 10.1016/S1474-4422(20)30432-4
Ciccone, A. et al. Corticosteroids for the long-term treatment in multiple sclerosis. Cochrane Database Syst. Rev. 23, CD006264 (2008).
Hauser, S. L. & Cree, B. A. C. Treatment of multiple sclerosis: a review. Am. J. Med. 133, 1380–1390.e2 (2020).
pubmed: 32682869
pmcid: 7704606
doi: 10.1016/j.amjmed.2020.05.049
Hacohen, Y. et al. Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurol. 75, 478–487 (2018).
pubmed: 29305608
pmcid: 5885190
doi: 10.1001/jamaneurol.2017.4601
Wang, X. et al. Effectiveness and tolerability of different therapies in preventive treatment of MOG-IgG-associated disorder: a network meta-analysis. Front. Immunol. 13, 953993 (2022).
pubmed: 35958613
pmcid: 9360318
doi: 10.3389/fimmu.2022.953993
Jarius, S. et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J. Neuroinflamm. 13, 280 (2016).
doi: 10.1186/s12974-016-0718-0
Corbali, O. & Chitnis, T. Pathophysiology of myelin oligodendrocyte glycoprotein antibody disease. Front. Neurol. 14, 1137998 (2023).
pubmed: 36925938
pmcid: 10011114
doi: 10.3389/fneur.2023.1137998
Dendrou, C. A., Fugger, L. & Friese, M. A. Immunopathology of multiple sclerosis. Nat. Rev. Immunol. 15, 545–558 (2015).
pubmed: 26250739
doi: 10.1038/nri3871
Yandamuri, S. S. et al. MOGAD patient autoantibodies induce complement, phagocytosis, and cellular cytotoxicity. JCI Insight 8, e165373 (2023).
pubmed: 37097758
pmcid: 10393237
doi: 10.1172/jci.insight.165373
Prüss, H. Autoantibodies in neurological disease. Nat. Rev. Immunol. 21, 798–813 (2021).
pubmed: 33976421
pmcid: 8111372
doi: 10.1038/s41577-021-00543-w
Sun, B., Ramberger, M., O’Connor, K. C., Bashford-Rogers, R. J. M. & Irani, S. R. The B cell immunobiology that underlies CNS autoantibody-mediated diseases. Nat. Rev. Neurol. 16, 481–492 (2020).
pubmed: 32724223
pmcid: 9364389
doi: 10.1038/s41582-020-0381-z
Kwon, Y. N. et al. Peripherally derived macrophages as major phagocytes in MOG encephalomyelitis. Neurol. Neuroimmunol. NeuroInflamm. 6, e60 (2019).
doi: 10.1212/NXI.0000000000000600
Saadoun, S. et al. Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain. Acta Neuropathol. Commun. 2, 35 (2014).
pubmed: 24685353
pmcid: 3977893
doi: 10.1186/2051-5960-2-35
Höftberger, R. et al. The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. Acta Neuropathol. 139, 875–892 (2020).
pubmed: 32048003
pmcid: 7181560
doi: 10.1007/s00401-020-02132-y
Lassmann, H. Multiple sclerosis: lessons from molecular neuropathology. Exp. Neurol. 262, 2–7 (2014).
pubmed: 24342027
doi: 10.1016/j.expneurol.2013.12.003
Calahorra, L., Camacho-Toledano, C., Serrano-Regal, M. P., Ortega, M. C. & Clemente, D. Regulatory cells in multiple sclerosis: from blood to brain. Biomedicines 10, 335 (2022).
pubmed: 35203544
pmcid: 8961785
doi: 10.3390/biomedicines10020335
Banwell, B. et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 22, 268–282 (2023).
pubmed: 36706773
doi: 10.1016/S1474-4422(22)00431-8
Villacieros‐Álvarez, J. et al. MOG antibodies in adults with a first demyelinating event suggestive of multiple sclerosis. Ann. Neurol. https://doi.org/10.1002/ana.26793 (2023).
Waters, P. J. et al. A multicenter comparison of MOG-IgG cell-based assays. Neurology 92, e1250–e1255 (2019).
pubmed: 30728305
pmcid: 6511109
doi: 10.1212/WNL.0000000000007096
Hyun, J.-W. et al. Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases. J. Neurol. Neurosurg. Psychiatry 88, 811–817 (2017).
pubmed: 28684532
doi: 10.1136/jnnp-2017-315998
Gastaldi, M. et al. Prognostic relevance of quantitative and longitudinal MOG antibody testing in patients with MOGAD: a multicentre retrospective study. J. Neurol. Neurosurg. Psychiatry 94, 201–210 (2023).
pubmed: 36460438
doi: 10.1136/jnnp-2022-330237
Waters, P. et al. Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes. JAMA Neurol. 77, 82–93 (2020).
pubmed: 31545352
doi: 10.1001/jamaneurol.2019.2940
Carta, S. et al. Significance of myelin oligodendrocyte glycoprotein antibodies in CSF: a retrospective multicenter study. Neurology 100, e1095–e1108 (2023).
pubmed: 36526426
pmcid: 10074465
doi: 10.1212/WNL.0000000000201662
Kim, H. J. & Palace, J. Should we test for IgG antibodies against MOG in both serum and CSF in patients with suspected MOGAD? Neurology 100, 497–498 (2023).
pubmed: 36526427
doi: 10.1212/WNL.0000000000206805
Kwon, Y. N. et al. Myelin oligodendrocyte glycoprotein-immunoglobulin G in the CSF: clinical implication of testing and association with disability. Neurol. Neuroimmunol. Neuroinflamm. 9, e1095 (2022).
pubmed: 34711644
doi: 10.1212/NXI.0000000000001095
Armangue, T. et al. Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. Lancet Neurol. 19, 234–246 (2020).
pubmed: 32057303
doi: 10.1016/S1474-4422(19)30488-0
de Mol, C. L. et al. The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults. Mult. Scler. 26, 806–814 (2020).
pubmed: 31094288
doi: 10.1177/1352458519845112
Wendel, E.-M. et al. High association of MOG-IgG antibodies in children with bilateral optic neuritis. Eur. J. Paediatr. Neurol. 27, 86–93 (2020).
pubmed: 32327391
doi: 10.1016/j.ejpn.2020.04.002
Yang, M. et al. Clinical predictive factors for diagnosis of MOG-IgG and AQP4-IgG related paediatric optic neuritis: a Chinese cohort study. Br. J. Ophthalmol. 106, 262–266 (2022).
pubmed: 33199301
doi: 10.1136/bjophthalmol-2020-317524
Chen, J. J. et al. MOG-IgG among participants in the pediatric optic neuritis prospective outcomes study. JAMA Ophthalmol. 139, 583–585 (2021).
pubmed: 33764379
pmcid: 7995133
doi: 10.1001/jamaophthalmol.2021.0349
Jurynczyk, M. et al. Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis. Brain 140, 617–627 (2017).
pubmed: 28364548
doi: 10.1093/brain/aww350
Cortese, R. et al. Clinical and MRI measures to identify non-acute MOG-antibody disease in adults. Brain 146, 2489–2501 (2022).
doi: 10.1093/brain/awac480
Carandini, T. et al. Distinct patterns of MRI lesions in MOG antibody disease and AQP4 NMOSD: a systematic review and meta-analysis. Mult. Scler. Relat. Disord. 54, 103118 (2021).
pubmed: 34246019
doi: 10.1016/j.msard.2021.103118
Carnero Contentti, E. et al. MRI to differentiate multiple sclerosis, neuromyelitis optica, and myelin oligodendrocyte glycoprotein antibody disease. J. Neuroimaging 33, 688–702 (2023).
pubmed: 37322542
doi: 10.1111/jon.13137
Varley, J. A. et al. Validation of the 2023 International Diagnostic criteria for MOGAD in a selected cohort of adults and children. Neurology 103, e209321 (2024).
pubmed: 38870448
pmcid: 11244737
doi: 10.1212/WNL.0000000000209321
Kim, K. H., Kim, S.-H., Park, N. Y., Hyun, J.-W. & Kim, H. J. Validation of the International MOGAD Panel proposed criteria. Mult. Scler. J. 29, 1680–1683 (2023).
doi: 10.1177/13524585231198754
Forcadela, M. et al. Timing of MOG-IgG testing is key to 2023 MOGAD diagnostic criteria. Neurol. Neuroimmunol. Neuroinflamm. 11, e200183 (2024).
pubmed: 37977848
doi: 10.1212/NXI.0000000000200183
Lipps, P. et al. Ongoing challenges in the diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurol. 80, 1377–1379 (2023).
pubmed: 37814961
pmcid: 10565644
doi: 10.1001/jamaneurol.2023.3956
Ciccarelli, O., Toosy, A. T., Thompson, A. & Hacohen, Y. Navigating through the recent diagnostic criteria for MOGAD: challenges and practicalities. Neurology 100, 689–690 (2023).
pubmed: 36878694
doi: 10.1212/WNL.0000000000207238
Lassmann, H. & Bradl, M. Multiple sclerosis: experimental models and reality. Acta Neuropathol. 133, 223–244 (2017).
pubmed: 27766432
doi: 10.1007/s00401-016-1631-4
Takai, Y. et al. Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study. Brain 143, 1431–1446 (2020).
pubmed: 32412053
doi: 10.1093/brain/awaa102
Gilli, F. & Ceccarelli, A. Magnetic resonance imaging approaches for studying mouse models of multiple sclerosis: a mini review. J. Neurosci. Res. 101, 1259–1274 (2023).
pubmed: 37001997
doi: 10.1002/jnr.25193
Sechi, E. et al. Comparison of MRI lesion evolution in different central nervous system demyelinating disorders. Neurology 97, e1097–e1109 (2021).
pubmed: 34261784
pmcid: 8456356
doi: 10.1212/WNL.0000000000012467
Beltrán, E. et al. Archeological neuroimmunology: resurrection of a pathogenic immune response from a historical case sheds light on human autoimmune encephalomyelitis and multiple sclerosis. Acta Neuropathol. 141, 67–83 (2021).
pubmed: 33242149
doi: 10.1007/s00401-020-02239-2
Carta, S. et al. Antibodies to MOG in CSF only: pathological findings support the diagnostic value. Acta Neuropathol. 141, 801–804 (2021).
pubmed: 33609159
doi: 10.1007/s00401-021-02286-3
Nicaise, A. M. et al. Cellular senescence in progenitor cells contributes to diminished remyelination potential in progressive multiple sclerosis. Proc. Natl Acad. Sci. USA 116, 9030–9039 (2019).
pubmed: 30910981
pmcid: 6500153
doi: 10.1073/pnas.1818348116
Junker, A. et al. Extensive subpial cortical demyelination is specific to multiple sclerosis. Brain Pathol. 30, 641–652 (2020).
pubmed: 31916298
pmcid: 8018087
doi: 10.1111/bpa.12813
Ciotti, J. R. et al. Central vein sign and other radiographic features distinguishing myelin oligodendrocyte glycoprotein antibody disease from multiple sclerosis and aquaporin-4 antibody-positive neuromyelitis optica. Mult. Scler. 28, 49–60 (2022).
pubmed: 33870786
doi: 10.1177/13524585211007086
Lassmann, H. Neuroinflammation: 2021 update. Free Neuropathol. 2, 1 (2021).
Wattjes, M. P. et al. 2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol. 20, 653–670 (2021).
pubmed: 34139157
doi: 10.1016/S1474-4422(21)00095-8
Soelberg, K. et al. A population-based prospective study of optic neuritis. Mult. Scler. J. 23, 1893–1901 (2017).
doi: 10.1177/1352458517734070
Asseyer, S. et al. Prodromal headache in MOG-antibody positive optic neuritis. Mult. Scler. Relat. Disord. 40, 101965 (2020).
pubmed: 32062443
doi: 10.1016/j.msard.2020.101965
Hassan, M. B. et al. Population-based incidence of optic neuritis in the era of aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies. Am. J. Ophthalmol. 220, 110–114 (2020).
pubmed: 32707199
pmcid: 8491771
doi: 10.1016/j.ajo.2020.07.014
Winter, A. & Chwalisz, B. MRI characteristics of NMO, MOG and MS related optic neuritis. Semin. Ophthalmol. 35, 333–342 (2020).
pubmed: 33395326
doi: 10.1080/08820538.2020.1866027
Vicini, R., Brügger, D., Abegg, M., Salmen, A. & Grabe, H. M. Differences in morphology and visual function of myelin oligodendrocyte glycoprotein antibody and multiple sclerosis associated optic neuritis. J. Neurol. 268, 276–284 (2021).
pubmed: 32785840
doi: 10.1007/s00415-020-10097-x
Falcão-Gonçalves, A. B., Bichuetti, D. B. & de Oliveira, E. M. L. Recurrent optic neuritis as the initial symptom in demyelinating diseases. J. Clin. Neurol. 14, 351–358 (2018).
pubmed: 29856159
pmcid: 6031992
doi: 10.3988/jcn.2018.14.3.351
Kraker, J. A. & Chen, J. J. An update on optic neuritis. J. Neurol. 270, 5113–5126 (2023).
pubmed: 37542657
doi: 10.1007/s00415-023-11920-x
Chen, J. J. et al. Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome. Am. J. Ophthalmol. 195, 8–15 (2018).
pubmed: 30055153
pmcid: 6371779
doi: 10.1016/j.ajo.2018.07.020
Oertel, F. C. et al. Longitudinal retinal changes in MOGAD. Ann. Neurol. 92, 476–485 (2022).
pubmed: 35703428
doi: 10.1002/ana.26440
Roca-Fernández, A. et al. The use of OCT in good visual acuity MOGAD and AQP4-NMOSD patients; with and without optic neuritis. Mult. Scler. J. Exp. Transl. Clin. 7, 20552173211066446 (2021).
pubmed: 35035989
pmcid: 8752955
Petzold, A. et al. Diagnosis and classification of optic neuritis. Lancet Neurol. 21, 1120–1134 (2022).
pubmed: 36179757
doi: 10.1016/S1474-4422(22)00200-9
Schroeder, A. et al. Detection of optic neuritis on routine brain MRI without and with the assistance of an image postprocessing algorithm. Am. J. Neuroradiol. 42, 1130–1135 (2021).
pubmed: 33737263
pmcid: 8191656
doi: 10.3174/ajnr.A7068
Petzold, A. et al. The investigation of acute optic neuritis: a review and proposed protocol. Nat. Rev. Neurol. 10, 447–458 (2014).
pubmed: 25002105
doi: 10.1038/nrneurol.2014.108
Riederer, I., Mühlau, M., Hoshi, M.-M., Zimmer, C. & Kleine, J. F. Detecting optic nerve lesions in clinically isolated syndrome and multiple sclerosis: double-inversion recovery magnetic resonance imaging in comparison with visually evoked potentials. J. Neurol. 266, 148–156 (2019).
pubmed: 30446963
doi: 10.1007/s00415-018-9114-2
Hodel, J. et al. Comparison of 3D double inversion recovery and 2D STIR FLAIR MR sequences for the imaging of optic neuritis: pilot study. Eur. Radiol. 24, 3069–3075 (2014).
pubmed: 25149294
doi: 10.1007/s00330-014-3342-3
Fadda, G. et al. Myelitis features and outcomes in CNS demyelinating disorders: comparison between multiple sclerosis, MOGAD, and AQP4-IgG-positive NMOSD. Front. Neurol. 13, 1011579 (2022).
pubmed: 36419536
pmcid: 9676369
doi: 10.3389/fneur.2022.1011579
Mariano, R. et al. Comparison of clinical outcomes of transverse myelitis among adults with myelin oligodendrocyte glycoprotein antibody vs aquaporin-4 antibody disease. JAMA Netw. Open 2, e1912732 (2019).
pubmed: 31596489
pmcid: 6802235
doi: 10.1001/jamanetworkopen.2019.12732
Sechi, E. et al. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management. Front. Neurol. 13, 885218 (2022).
pubmed: 35785363
pmcid: 9247462
doi: 10.3389/fneur.2022.885218
Budhram, A. et al. Unilateral cortical FLAIR-hyperintense lesions in anti-MOG-associated encephalitis with seizures (FLAMES): characterization of a distinct clinico-radiographic syndrome. J. Neurol. 266, 2481–2487 (2019).
pubmed: 31243540
doi: 10.1007/s00415-019-09440-8
Budhram, A., Sechi, E., Nguyen, A., Lopez-Chiriboga, A. S. & Flanagan, E. P. FLAIR-hyperintense lesions in anti-MOG-associated encephalitis with seizures (FLAMES): is immunotherapy always needed to put out the fire? Mult. Scler. Relat. Disord. 44, 102283 (2020).
pubmed: 32562909
doi: 10.1016/j.msard.2020.102283
Wang, Y.-F. et al. The clinical features of FLAIR-hyperintense lesions in anti-MOG antibody associated cerebral cortical encephalitis with seizures: case reports and literature review. Front. Immunol. 12, 582768 (2021).
pubmed: 34177880
pmcid: 8231650
doi: 10.3389/fimmu.2021.582768
Banks, S. A. et al. Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS. J. Neurol. Neurosurg. Psychiatry 92, 384–390 (2020).
doi: 10.1136/jnnp-2020-325121
Jarius, S. et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: brainstem involvement — frequency, presentation and outcome. J. Neuroinflamm. 13, 281 (2016).
doi: 10.1186/s12974-016-0719-z
Kunchok, A. et al. Does area postrema syndrome occur in myelin oligodendrocyte glycoprotein-IgG-associated disorders (MOGAD)? Neurology 94, 85–88 (2020).
pubmed: 31827002
doi: 10.1212/WNL.0000000000008786
Zhao-Fleming, H. H. et al. CNS demyelinating attacks requiring ventilatory support with myelin oligodendrocyte glycoprotein or aquaporin-4 antibodies. Neurology 97, e1351–e1358 (2021).
pubmed: 34389648
pmcid: 8480400
doi: 10.1212/WNL.0000000000012599
Sinha, S. et al. Hemicraniectomy and externalized ventricular drain placement in a pediatric patient with myelin oligodendrocyte glycoprotein-associated tumefactive demyelinating disease. Childs Nerv. Syst. 38, 185–189 (2022).
pubmed: 33796928
doi: 10.1007/s00381-021-05139-2
McLendon, L. A. et al. Dramatic response to anti-IL-6 receptor therapy in children with life-threatening myelin oligodendrocyte glycoprotein-associated disease. Neurol. Neuroimmunol. Neuroinflamm. 10, e200150 (2023).
pubmed: 37582615
pmcid: 10427143
doi: 10.1212/NXI.0000000000200150
Hümmert, M. W. et al. Cognition in patients with neuromyelitis optica spectrum disorders: a prospective multicentre study of 217 patients (CogniNMO-Study). Mult. Scler. 29, 819–831 (2023).
pubmed: 36786424
pmcid: 10278388
doi: 10.1177/13524585231151212
Juryńczyk, M., Jacob, A., Fujihara, K. & Palace, J. Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations. Pract. Neurol. 19, 187–195 (2019).
pubmed: 30530724
doi: 10.1136/practneurol-2017-001787
Yılmaz, Ü., Edizer, S., Songür, Ç. Y., Güzin, Y. & Durak, F. S. Atypical presentation of MOG-related disease: slowly progressive behavioral and personality changes following a seizure. Mult. Scler. Relat. Disord. 36, 101394 (2019).
pubmed: 31525625
doi: 10.1016/j.msard.2019.101394
Jarius, S. et al. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: results from 163 lumbar punctures in 100 adult patients. J. Neuroinflamm. 17, 261 (2020).
doi: 10.1186/s12974-020-01824-2
Sechi, E. et al. Variability of cerebrospinal fluid findings by attack phenotype in myelin oligodendrocyte glycoprotein-IgG-associated disorder. Mult. Scler. Relat. Disord. 47, 102638 (2021).
pubmed: 33276239
doi: 10.1016/j.msard.2020.102638
Tintoré, M. et al. Isolated demyelinating syndromes: comparison of CSF oligoclonal bands and different MR imaging criteria to predict conversion to CDMS. Mult. Scler. J. 7, 359–363 (2001).
doi: 10.1177/135245850100700603
Dobson, R., Ramagopalan, S., Davis, A. & Giovannoni, G. Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude. J. Neurol. Neurosurg. Psychiatry 84, 909–914 (2013).
pubmed: 23431079
doi: 10.1136/jnnp-2012-304695
Ramanathan, S. et al. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. Mult. Scler. 22, 470–482 (2016).
pubmed: 26163068
doi: 10.1177/1352458515593406
Dubey, D. et al. Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody. JAMA Neurol. 76, 301–309 (2019).
pubmed: 30575890
doi: 10.1001/jamaneurol.2018.4053
Tzanetakos, D. et al. Cortical involvement and leptomeningeal inflammation in myelin oligodendrocyte glycoprotein antibody disease: a three-dimensional fluid-attenuated inversion recovery MRI study. Mult. Scler. 28, 718–729 (2022).
pubmed: 34410179
doi: 10.1177/13524585211034362
Ogawa, R. et al. MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. Neurol. Neuroimmunol. Neuroinflamm. 4, e322 (2017).
pubmed: 28105459
pmcid: 5241006
doi: 10.1212/NXI.0000000000000322
Budhram, A., Kunchok, A. C. & Flanagan, E. P. Unilateral leptomeningeal enhancement in myelin oligodendrocyte glycoprotein immunoglobulin G-associated disease. JAMA Neurol. 77, 648 (2020).
pubmed: 32119057
doi: 10.1001/jamaneurol.2020.0001
Salama, S., Khan, M., Pardo, S., Izbudak, I. & Levy, M. MOG antibody-associated encephalomyelitis/encephalitis. Mult. Scler. J. 25, 1427–1433 (2019).
doi: 10.1177/1352458519837705
Elsbernd, P. et al. Cerebral enhancement in MOG antibody-associated disease. J. Neurol. Neurosurg. Psychiatry 95, 14–18 (2023).
pubmed: 37221051
doi: 10.1136/jnnp-2023-331137
Salama, S., Khan, M., Levy, M. & Izbudak, I. Radiological characteristics of myelin oligodendrocyte glycoprotein antibody disease. Mult. Scler. Relat. Disord. 29, 15–22 (2019).
pubmed: 30658259
pmcid: 6431795
doi: 10.1016/j.msard.2019.01.021
Chia, N. H., Redenbaugh, V., Chen, J. J., Pittock, S. J. & Flanagan, E. P. Corpus callosum involvement in MOG antibody-associated disease in comparison to AQP4-IgG-seropositive neuromyelitis optica spectrum disorder and multiple sclerosis. Mult. Scler. 29, 748–752 (2023).
pubmed: 36691800
pmcid: 10175177
doi: 10.1177/13524585221150743
Cai, M.-T., Zhang, Y.-X., Zheng, Y., Fang, W. & Ding, M.-P. Callosal lesions on magnetic resonance imaging with multiple sclerosis, neuromyelitis optica spectrum disorder and acute disseminated encephalomyelitis. Mult. Scler. Relat. Disord. 32, 41–45 (2019).
pubmed: 31030018
doi: 10.1016/j.msard.2019.04.019
Mastrangelo, V. et al. Bilateral extensive corticospinal tract lesions in MOG antibody-associated disease. Neurology 95, 648–649 (2020).
pubmed: 32817179
doi: 10.1212/WNL.0000000000010662
Hacohen, Y. et al. ‘Leukodystrophy-like’ phenotype in children with myelin oligodendrocyte glycoprotein antibody-associated disease. Dev. Med. Child Neurol. 60, 417–423 (2018).
pubmed: 29288492
doi: 10.1111/dmcn.13649
Baumann, M. et al. MRI of the first event in pediatric acquired demyelinating syndromes with antibodies to myelin oligodendrocyte glycoprotein. J. Neurol. 265, 845–855 (2018).
pubmed: 29423614
doi: 10.1007/s00415-018-8781-3
Maranzano, J. et al. MRI evidence of acute inflammation in leukocortical lesions of patients with early multiple sclerosis. Neurology 89, 714–721 (2017).
pubmed: 28724581
pmcid: 5562966
doi: 10.1212/WNL.0000000000004227
Cortese, R. et al. Differentiating multiple sclerosis from AQP4-neuromyelitis optica spectrum disorder and MOG-antibody disease with imaging. Neurology 100, e308–e323 (2023).
pubmed: 36192175
pmcid: 9869760
doi: 10.1212/WNL.0000000000201465
Messina, S. et al. Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis. Mult. Scler. 28, 217–227 (2022).
pubmed: 34048323
doi: 10.1177/13524585211018987
Biotti, D. et al. Optic neuritis in patients with anti-MOG antibodies spectrum disorder: MRI and clinical features from a large multicentric cohort in France. J. Neurol. 264, 2173–2175 (2017).
pubmed: 28914353
doi: 10.1007/s00415-017-8615-8
Carnero Contentti, E. et al. Chiasmatic lesions on conventional magnetic resonance imaging during the first event of optic neuritis in patients with neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein‐associated disease in a Latin American cohort. Eur. J. Neurol. 29, 802–809 (2022).
pubmed: 34799965
doi: 10.1111/ene.15178
Fadda, G. et al. MRI and laboratory features and the performance of international criteria in the diagnosis of multiple sclerosis in children and adolescents: a prospective cohort study. Lancet Child. Adolesc. Health 2, 191–204 (2018).
pubmed: 30169254
doi: 10.1016/S2352-4642(18)30026-9
Cobo-Calvo, A. et al. Cranial nerve involvement in patients with MOG antibody-associated disease. Neurol. Neuroimmunol. Neuroinflamm. 6, e543 (2019).
pubmed: 30800725
pmcid: 6384017
doi: 10.1212/NXI.0000000000000543
Haider, L. et al. Cranial nerve enhancement in multiple sclerosis is associated with younger age at onset and more severe disease. Front. Neurol. 10, 1085 (2019).
pubmed: 31781014
pmcid: 6851051
doi: 10.3389/fneur.2019.01085
Denève, M. et al. MRI features of demyelinating disease associated with anti-MOG antibodies in adults. J. Neuroradiol. 46, 312–318 (2019).
pubmed: 31228536
doi: 10.1016/j.neurad.2019.06.001
Pekcevik, Y. et al. Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging. Mult. Scler. 22, 302–311 (2016).
pubmed: 26209588
doi: 10.1177/1352458515591069
Mariano, R. et al. Quantitative spinal cord MRI in MOG-antibody disease, neuromyelitis optica and multiple sclerosis. Brain 144, 198–212 (2021).
pubmed: 33206944
doi: 10.1093/brain/awaa347
Webb, L. M. et al. Marked central canal T2-hyperintensity in MOGAD myelitis and comparison to NMOSD and MS. J. Neurol. Sci. 450, 120687 (2023).
pubmed: 37201267
pmcid: 10492002
doi: 10.1016/j.jns.2023.120687
Mohseni, S. H. et al. Leptomeningeal and intraparenchymal blood barrier disruption in a MOG-IgG-positive patient. Case Rep. Neurol. Med. 2018, 1365175 (2018).
pubmed: 30834146
pmcid: 6374805
El Naggar, I. et al. MR imaging in children with transverse myelitis and acquired demyelinating syndromes. Mult. Scler. Relat. Disord. 67, 104068 (2022).
pubmed: 35933757
doi: 10.1016/j.msard.2022.104068
Fadda, G. et al. Comparison of spinal cord magnetic resonance imaging features among children with acquired demyelinating syndromes. JAMA Netw. Open 4, e2128871 (2021).
pubmed: 34643718
pmcid: 8515204
doi: 10.1001/jamanetworkopen.2021.28871
Cacciaguerra, L. et al. Timing and predictors of T2-lesion resolution in patients with myelin-oligodendrocyte-glycoprotein-antibody-associated disease. Neurology 101, e1376–e1381 (2023).
pubmed: 37336767
doi: 10.1212/WNL.0000000000207478
Abdel-Mannan, O. et al. Evolution of brain MRI lesions in paediatric myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and its relevance to disease course. J. Neurol. Neurosurg. Psychiatry 95, 426–433 (2023).
Kitley, J. et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies. JAMA Neurol. 71, 276 (2014).
pubmed: 24425068
doi: 10.1001/jamaneurol.2013.5857
Fadda, G. et al. Silent new brain MRI lesions in children with MOG-antibody associated disease. Ann. Neurol. 89, 408–413 (2021).
pubmed: 33210746
doi: 10.1002/ana.25957
Verhey, L. H. et al. Clinical and MRI activity as determinants of sample size for pediatric multiple sclerosis trials. Neurology 81, 1215–1221 (2013).
pubmed: 23966255
pmcid: 3795606
doi: 10.1212/WNL.0b013e3182a6cb9b
Camera, V. et al. Frequency of new silent MRI lesions in myelin oligodendrocyte glycoprotein antibody disease and aquaporin-4 antibody neuromyelitis optica spectrum disorder. JAMA Netw. Open 4, e2137833 (2021).
pubmed: 34878547
pmcid: 8655599
doi: 10.1001/jamanetworkopen.2021.37833
Syc-Mazurek, S. B. et al. Frequency of new or enlarging lesions on MRI outside of clinical attacks in patients with MOG-antibody-associated disease. Neurology 99, 795–799 (2022).
pubmed: 36175150
pmcid: 9651461
doi: 10.1212/WNL.0000000000201263
Schmidt, F. A. et al. Differences in advanced magnetic resonance imaging in MOG-IgG and AQP4-IgG seropositive neuromyelitis optica spectrum disorders: a comparative study. Front. Neurol. 11, 499910 (2020).
pubmed: 33101166
pmcid: 7554609
doi: 10.3389/fneur.2020.499910
Chien, C. et al. Spinal cord lesions and atrophy in NMOSD with AQP4-IgG and MOG-IgG associated autoimmunity. Mult. Scler. J. 25, 1926–1936 (2019).
doi: 10.1177/1352458518815596
Duan, Y. et al. Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS. J. Neurol. Neurosurg. Psychiatry 92, 709–716 (2021).
pubmed: 33687975
doi: 10.1136/jnnp-2020-324826
Lotan, I. et al. Volumetric brain changes in MOGAD: a cross-sectional and longitudinal comparative analysis. Mult. Scler. Relat. Disord. 69, 104436 (2023).
pubmed: 36512956
doi: 10.1016/j.msard.2022.104436
Rechtman, A. et al. Volumetric brain loss correlates with a relapsing MOGAD disease course. Front. Neurol. 13, 867190 (2022).
pubmed: 35401390
pmcid: 8987978
doi: 10.3389/fneur.2022.867190
Zhuo, Z. et al. Brain structural and functional alterations in MOG antibody disease. Mult. Scler. J. 27, 1350–1363 (2021).
doi: 10.1177/1352458520964415
Fadda, G. et al. Deviation from normative whole brain and deep gray matter growth in children with MOGAD, MS, and monophasic seronegative demyelination. Neurology 101, e425–e437 (2023).
pubmed: 37258297
pmcid: 10435061
doi: 10.1212/WNL.0000000000207429
Gao, C. et al. Structural and functional alterations in visual pathway after optic neuritis in MOG antibody disease: a comparative study with AQP4 seropositive NMOSD. Front. Neurol. 12, 673472 (2021).
pubmed: 34177778
pmcid: 8220215
doi: 10.3389/fneur.2021.673472
Brier, M. R. et al. Quantitative MRI identifies lesional and non-lesional abnormalities in MOGAD. Mult. Scler. Relat. Disord. 73, 104659 (2023).
pubmed: 37004272
pmcid: 10994694
doi: 10.1016/j.msard.2023.104659
Castellaro, M. et al. The use of the central vein sign in the diagnosis of multiple sclerosis: a systematic review and meta-analysis. Diagnostics 10, 1025 (2020).
pubmed: 33260401
pmcid: 7760678
doi: 10.3390/diagnostics10121025
Cagol, A. et al. Diagnostic performance of cortical lesions and the central vein sign in multiple sclerosis. JAMA Neurol. 81, 143–153 (2024).
pubmed: 38079177
doi: 10.1001/jamaneurol.2023.4737
Clarke, M. A. et al. Paramagnetic rim lesions and the central vein sign: characterizing multiple sclerosis imaging markers. J. Neuroimaging 34, 86–94 (2024).
pubmed: 38018353
doi: 10.1111/jon.13173
Sinnecker, T. et al. MRI phase changes in multiple sclerosis vs neuromyelitis optica lesions at 7 T. Neurol. Neuroimmunol. Neuroinflamm. 3, e259 (2016).
pubmed: 27489865
pmcid: 4959510
doi: 10.1212/NXI.0000000000000259
Juryńczyk, M., Jakuszyk, P., Kurkowska-Jastrzębska, I. & Palace, J. Increasing role of imaging in differentiating MS from non-MS and defining indeterminate borderline cases. Neurol. Neurochir. Pol. 56, 210–219 (2021).
pubmed: 34664709
doi: 10.5603/PJNNS.a2021.0077
Sacco, S. et al. Susceptibility-based imaging aids accurate distinction of pediatric-onset MS from myelin oligodendrocyte glycoprotein antibody-associated disease. Mult. Scler. 29, 1736–1747 (2023).
pubmed: 37897254
pmcid: 10687802
doi: 10.1177/13524585231204414
Harrison, K. L. et al. Central vein sign in pediatric multiple sclerosis and myelin oligodendrocyte glycoprotein antibody-associated disease. Pediatr. Neurol. 146, 21–25 (2023).
pubmed: 37406422
doi: 10.1016/j.pediatrneurol.2023.05.013
Clarke, L. et al. Magnetic resonance imaging in neuromyelitis optica spectrum disorder. Clin. Exp. Immunol. 206, 251–265 (2021).
pubmed: 34080180
pmcid: 8561702
doi: 10.1111/cei.13630
Matthews, L. et al. Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology 80, 1330–1337 (2013).
pubmed: 23486868
pmcid: 3656462
doi: 10.1212/WNL.0b013e3182887957
Juryńczyk, M. et al. Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease. J. Neurol. Neurosurg. Psychiatry 88, 132–136 (2017).
pubmed: 27951522
doi: 10.1136/jnnp-2016-314005
Huh, S.-Y. et al. The usefulness of brain MRI at onset in the differentiation of multiple sclerosis and seropositive neuromyelitis optica spectrum disorders. Mult. Scler. 20, 695–704 (2014).
pubmed: 24072726
doi: 10.1177/1352458513506953
Carnero Contentti, E. et al. Towards imaging criteria that best differentiate MS from NMOSD and MOGAD: large multi-ethnic population and different clinical scenarios. Mult. Scler. Relat. Disord. 61, 103778 (2022).
pubmed: 35452969
doi: 10.1016/j.msard.2022.103778
Bensi, C. et al. Brain and spinal cord lesion criteria distinguishes AQP4-positive neuromyelitis optica and MOG-positive disease from multiple sclerosis. Mult. Scler. Relat. Disord. 25, 246–250 (2018).
pubmed: 30144694
doi: 10.1016/j.msard.2018.08.008
Cacciaguerra, L. et al. Brain and cord imaging features in neuromyelitis optica spectrum disorders. Ann. Neurol. 85, 371–384 (2019).
pubmed: 30635936
doi: 10.1002/ana.25411
Solomon, A. J. et al. Differential diagnosis of suspected multiple sclerosis: an updated consensus approach. Lancet Neurol. 22, 750–768 (2023).
pubmed: 37479377
doi: 10.1016/S1474-4422(23)00148-5
Abdel‐Mannan, O. et al. Incidence of paediatric multiple sclerosis and other acquired demyelinating syndromes: 10‐year follow‐up surveillance study. Dev. Med. Child Neurol. 64, 502–508 (2022).
pubmed: 34693523
doi: 10.1111/dmcn.15098
Hacohen, Y. et al. Diagnostic algorithm for relapsing acquired demyelinating syndromes in children. Neurology 89, 269–278 (2017).
pubmed: 28615429
doi: 10.1212/WNL.0000000000004117